Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 19/20 | 0.65 |
| ▸ | CNR2 | P34972 | 14/20 | 0.65 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1040785 | 0.92 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL4615166 | 0.89 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL4925132 | 0.89 | CNR1 (0.55) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL663968 | 0.88 | CNR1 (0.66) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL30961559 | 0.88 | CNR1 (0.66) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL24238334 | 0.88 | CNR1 (0.66) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL30961585 | 0.88 | CNR1 (0.66) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4923284 | 0.88 | CNR1 (0.54) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4517281 | 0.87 | CNR1 (0.69) | CNR1CNR2 | |
| SCHEMBL4616826 | 0.86 | CNR1 (0.69) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729101-B2 | 1H-imidazole derivative having CB1, agonistic, CB1 partial agonistic or CB1 antagnistic activity | SOLVAY PHARMACEUTICALS, B.V. (NL) | 2014-05-20 | — | — | US | disclosed |
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. | 2009-07-16 | — | — | US | disclosed |
| US-20080319019-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080319019-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080319019-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| EP-1438296-B1 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARM BV (NL) | 2008-11-26 | — | — | EP | disclosed |
| EP-1833802-A2 | 1,2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-7109216-B2 | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-09-19 | — | — | US | disclosed |
| WO-2006067428-A2 | 1, 2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. | 2005-03-10 | — | — | US | disclosed |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
| EP-1438296-A2 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003027076-A2 | 1H-IMIDAZOLE DERIVATIVES HAVING CB1 AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1- ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181949-A1 | 1H-IMIDAZOLE DERIVATIVE HAVING CB1, AGONISTIC, CB1 PARTIAL AGONISTIC OR CB1 ANTAGNISTIC ACTIVITY | CNR1, CNR2, CHRM1 | CNR1 1/4885CNR2 2/4885GABRA2 67/4885 |
| US-20040235854-A1 | 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity | CNR1, CNR2, CHRM1 | CNR1 1/4885CNR2 2/4885GABRA2 75/4885 |
| US-20050054679-A1 | 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | CNR1, CNR2, HRH4 | CNR1 1/4885CNR2 2/4885GABRA2 74/4885 |
| US-20080319019-A1 | Therapeutic Agents | SDHA, GPR119, ABAT | CNR1 393/4885CNR2 413/4885GABRA2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.